We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chemists Synthesize a Common Antibiotic

By Biotechdaily staff writers
Posted on 31 Mar 2006
Researchers have synthesized the antibiotic nisin and have determined its crystal structure and the mechanism that controls its antibacterial enzyme activity.

Nisin is an inhibitory polycyclic peptide with 34 amino acid residues and is used as a food preservative. More...
It contains the uncommon amino acids lanthionine, methyllanthionine, dehydroalanine, and dehydro-amino-butyric acid. These special amino acids are synthesized by posttranslational modifications. In these reactions, a ribosomally synthesized 57 amino acid peptide is converted to the final peptide. The unsaturated amino acids originate from serine and threonine.

Nisin is produced by fermentation using the bacterium Lactococcus lactis. Commercially it is obtained from natural substrates including milk and is not chemically synthesized. It is used in processed cheese production to extend shelf life by suppressing Gram-positive spoilage and pathogenic bacteria. Due to its highly selective spectrum of activity it is also employed as an agent in microbiologic media for the isolation of gram-negative bacteria, yeast, and molds.

Investigators at the University of Illinois (Urbana-Champaign, USA) used a single cyclase enzyme to re-create the synthetic process that normally occurs in L lactis. Results published in the March 10, 2006, issue of Science revealed that the NisC (nisin cyclase) enzyme catalyzes the formation of ten new chemical bonds in a stereochemically defined fashion, resulting in the five characteristic thioether rings required for nisin's biologic activity.

"Despite all the progress in synthetic chemistry, we cannot come close to making a compound like nisin efficiently,” said contributing author Dr. Wilfred A. van der Donk, professor of chemistry at the University of Illinois. "Synthetic chemists in the past needed 67 steps to make it, while nature uses just two enzymes. One of these is the cyclase whose activity we have demonstrated in this paper.”



Related Links:
University of Illinois

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.